神农科技(300189) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥47,237,741.65, representing a 28.27% increase compared to ¥36,826,602.08 in the same period last year[3] - The net profit attributable to shareholders was -¥4,053,976.37, a significant decline of 899.29% from -¥405,687.61 year-on-year[3] - The net cash flow from operating activities was -¥23,119,814.75, a decrease of 631.96% compared to ¥4,346,136.10 in the previous year[3] - Total operating revenue for the first quarter was CNY 47,237,741.65, an increase of 28.5% compared to CNY 36,826,602.08 in the previous period[23] - The net loss for the period was CNY 5,188,590.74, compared to a net loss of CNY 1,204,029.72 in the previous period, indicating a worsening of 331.5%[24] - The total comprehensive income attributable to the parent company was -4,053,976.37 CNY, compared to -405,687.61 CNY in the previous period, indicating a significant decline[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,056,272,471.23, down 7.39% from ¥1,140,601,046.20 at the end of the previous year[3] - Total liabilities decreased to CNY 109,532,250.32 from CNY 188,672,234.55, a reduction of 42.0%[21] - Cash and cash equivalents decreased to CNY 143,185,989.56 from CNY 219,061,037.57, a decline of 34.6%[20] - The total assets decreased to CNY 1,056,272,471.23 from CNY 1,140,601,046.20, a decline of 7.4%[21] Cash Flow - Cash inflows from operating activities totaled 33,801,424.19 CNY, down 65.2% from 97,269,409.46 CNY in the previous year[26] - Cash outflows from operating activities amounted to 56,921,238.94 CNY, compared to 92,923,273.36 CNY in the previous period, reflecting a reduction of 38.7%[27] - The net cash flow from investing activities was -62,786,002.40 CNY, a decline from 19,289,109.07 CNY in the previous year[27] - Cash inflows from investment activities were 182,413,428.28 CNY, a decrease from 317,093,708.07 CNY in the previous year[27] - The company incurred cash outflows from investment activities totaling 245,199,430.68 CNY, down from 297,804,599.00 CNY in the previous period[27] Shareholder Information - The company’s major shareholders include Cao Oujie with 122,715,849 shares (approximately 19.5%), and Hunan Hongde Asset Management Co., Ltd. with 51,028,330 shares (approximately 8.0%)[13] - The top ten shareholders do not have any associated relationships or act in concert as per the regulations.[13] - The company has received multiple requests from Hunan Hongde regarding the equity transfer, indicating ongoing negotiations and potential changes in ownership structure.[16] - The company is actively managing its shareholder relations and addressing proposals for extraordinary general meetings to discuss significant transactions.[16] Legal and Equity Transfer - The company plans to transfer 100% equity of its wholly-owned subsidiary, Hainan Baoting Nanfan Seed Industry, for no less than RMB 173 million (approximately $26.5 million) to Hainan Hailisi Medical Equipment Co., Ltd.[15] - The transfer price agreed upon with Hainan Hailisi Medical is RMB 183 million (approximately $28 million), with a deposit of RMB 36.6 million (approximately $5.6 million) already received.[15] - The company has faced legal proceedings related to the equity transfer, with a civil judgment issued on June 28, 2021, and the case concluded by March 31, 2022.[17] - As of March 31, 2022, the company has resolved the litigation concerning the equity transfer, and the court has lifted the seizure of land use rights for the subsidiary.[17] Investment and Income - The company reported a 381.49% increase in investment income, amounting to an increase of ¥2,684,800.00 from equity method investments[8] - The company reported an investment income of CNY 3,388,599.45, significantly higher than CNY 703,775.36 in the previous period[24] Operational Metrics - The company experienced a 59.04% decrease in contract liabilities, down by ¥10,183,200.00, as subsidiaries delivered goods to prepaid customers[8] - The company received government subsidies amounting to ¥617,906.39, which are closely related to its normal business operations[5] - Research and development expenses were CNY 2,721,609.36, down from CNY 3,650,600.62, a decrease of 25.5%[24] - The company has not conducted an audit for the first quarter report[28]